AAPG vs IONS โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
IONS Captures Institutional Edge (2โ2 Pillars ยท 7โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Ionis Pharmaceuticals, Inc. Common Stock (IONS) driven by superior Growth & Margin, Momentum & Technical while AAPG counters with relative strength in Valuation, Options & Structure. Fundamentally, AAPG trades at 9.7x Forward P/E with -219.5% operating margin (+29.3% YoY revenue) versus IONS at 90.9x Forward P/E and -58.8% operating margin (+54.9% YoY). In options structure, AAPG sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against IONS sits in BREAKDOWN (17th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | AAPG | IONS | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.4B | $4.7B | Larger Scale | IONS |
| Trailing P/E Ratio Valuation | 9.7x | 90.9x | Lower Multiple | AAPG |
| Forward P/E Ratio Valuation | 9.7x | 90.9x | Lower Multiple | AAPG |
| Revenue Growth (YoY) Growth | +29.3% | +54.9% | Higher Growth | IONS |
| Operating Margin (TTM) Profitability | -219.5% | -58.8% | Higher Margin | IONS |
| Net Profit Margin Profitability | -228.5% | -56.9% | Higher Margin | IONS |
| Return on Equity (ROE) Capital Efficiency | -236.6% | -108.0% | Higher ROE | IONS |
| 52-Week Range Position Momentum | 0% ($13โ$34) | 2% ($27โ$87) | Stronger Trend | IONS |
| Beta / 30D Volatility Risk Regime | 1.31ฮฒ ยท 69% Vol | 0.18ฮฒ ยท 86% Vol | Lower Realized Risk | AAPG |
| Unified Institutional Score Composite Signal | 50.2 / 100 (HOLD) | 63.9 / 100 (BUY) | Higher Composite | IONS |